Tissuechips Applications
Tissue chip devices are designed as accurate models of the structure and performance of human organs, like the lungs, liver and heart. Once developed and integrated, researchers can use these models to predict whether a candidate drug,
vaccine or biologic agent is safe or toxic in humans during a faster and more effective way than current methods.
The ultimate goal of the program is to accelerate the interpretation of basic discoveries into the clinic. By creating an integrated human body-on-a-chip, researchers can test the varied potential effects of a substance such as a drug across the entire body before any testing in humans.
A small device that contains human cells during a 3D matrix represents an enormous leap within the ability of scientists to check how those cells answer stresses,
drugs and genetic changes. About the dimensions of a thumb drive, the devices are referred to as tissue chips or organs on chips.
The high rate of failure during
drug development is well-known, however recent advances in
tissue engineering and microfabrication have contributed to the event of microphysiological systems (MPS), or ‘organs-on-chips’ that recapitulate the function of human organs. These ‘tissue chips’ might be utilized for drug
screening and safety testing to potentially transform the first stages of the
drug development process.
High Impact List of Articles
-
Nursing to regulator, rowing to digital health
Elin Haf Davies
Interview: Clinical Investigation
-
Nursing to regulator, rowing to digital health
Elin Haf Davies
Interview: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Jing-Xin Li, Feng-Cai Zhu
Editorial: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
Research Article: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe
Finn Akerstrm, Luis Rodriguez-Padial
Review Article: Clinical Investigation
-
The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe
Finn Akerstrm, Luis Rodriguez-Padial
Review Article: Clinical Investigation
Relevant Topics in Clinical